CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth quarter, while reiterating expectations for top-line data from a separate Phase 3 trial in the first half of the year.
Barrick Mining: On Track For A Strong Year-End Special Dividend
Barrick Mining Corporation is demonstrating improved operational performance and strong cash flow in the current price environment. B beat gold production guidance in Q1, lowered all-in sustaining costs, and maintained full-year output targets, with significant progress at North American and African mines. A new $3 billion buyback and a year-end top-up dividend policy could provide a 3.2% forward yield, best-in-class among big gold miners.
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance.
Electronic Arts Revenue Up as Net Bookings Grow; Buyout Deal Remains on Track
The videogame maker said net bookings—a measure that combines total net revenue and the change in deferred net revenue for online-enabled games—rose to $1.86 billion from $1.8 billion.
IYRI: Covered Call REIT ETF, Strong Distribution Yield, Short, Adequate Track-Record
Neos is an investment manager with several strong, high-growth covered call ETFs. IYRI is one such ETF, focusing on REITs. It has similar characteristics to most covered call ETFs, namely a strong distribution yield, currently reaching 10.9%, but below-average potential capital gains. It's a young fund, with inception in early 2025, and has performed adequately since.
Archer Aviation: Too Cheap To Ignore As Flights Are On Track
Archer Aviation is reiterated as a buy, with commercialization imminent and valuation at historically low levels. ACHR achieved a key FAA certification milestone, positioning it as a first mover with flights expected in the U.S. and UAE this year. Significant cash reserves support near-term operations, but recent heavy dilution and ongoing legal risks warrant close monitoring.
Atour Lifestyle: Hotel Expansion Remains On Track
Atour Lifestyle Holdings Limited again reported strong results for Q4. The manachised hotel growth pipeline remains strong, driving asset light earnings growth for ATAT. ATAT reported record retail revenues as the brand continues to grow in awareness.
7 Ways The Train Could Go Off The Track For Nvidia
7 Ways The Train Could Go Off The Track For Nvidia
Bonterra Energy: Growth Strategy On Track
Bonterra Energy acquires more Charlie Lake acreage. The recent Charlie Lake acquisition enables production growth with fewer wells. Transitioning toward liquids production enhances profitability.
3 Standout ETFs With a Proven Track Record of Success
The world of exchange-traded funds (ETFs) expands and changes at a rapid pace, with investors funneling more than a trillion dollars into these products annually amid a host of new fund launches. It can be easy to get caught up in the noise of the ETF space as a result.
OMAH: Berkshire Hathaway Covered Call Income ETF, Strong Distribution Yield, Short Track Record
OMAH's equity portfolio mirrors Berkshire Hathaway's top holdings, plus direct BRK exposure. Income is boosted with covered calls, resulting in a 14.3% distribution yield. Upside potential is limited. OMAH has performed quite well in the past, but it's a young fund, and an expensive one, with a 0.95% expense ratio.
Financial Institutions, Inc.: Back On Track After A Challenging Year
Financial Institutions, Inc. rebounded after a challenging 2024 marked by restructuring and significant losses. The company's return on assets reached 1.27% in Q4 2025, and return on equity came in at an impressive 12.53%. After ending 2024 at $24.45, tangible book value per share for FISI rose to $27.84 at the end of 2025, a 13.9% improvement.
